NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

CompletedNA

Sponsor: HealthPartners Institute

Conditions: Type 2 Diabetes

Interventions: CGM Group, SMBG Group

Countries: United States

The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes. The secondary objective is to determine the benefit of using CGM for clinical diabetes management decision-making.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Male or female ≥18 and ≤75 years of age (Upper range to assure dexterity for use of CGM)
* Clinical diagnosis of type 2 diabetes
* HbA1c ≥7.0%
* Diabetes can be treated with any of the following therapies within one month prior to study enrollment: (1) medical nutrition therapy alone or with metformin; (2) sulfonylurea with or without metformin; (3) dipeptidyl peptidase 4 (DPP-4) inhibitor or Glucagon-like peptide-1 (GLP-1) agonist with or without metformin; or insulin with or without metformin.

Exclusion Criteria:

* Treated with Thiazolidinediones (TZD)
* Administered prednisone or cortisone medications in the previous 30 days
* Currently pregnant or planning pregnancy during the study period
* Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study
* HbA1c \<7.0%
* Unable to follow the study protocol
* Unable to speak, read and write in English

Locations (1)

Minneapolis, Minnesota, United States